N
Neurophth
Biotech & Life Sciences · Wuhan, China · Founded 2016
Dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally MoreLess
Neurophth is a clinical-stage gene therapy company focused on the development of treatments for ophthalmic diseases. The company was founded in 2016 by Professor Bin Li, a leading expert in ophthalmology and gene therapy.
Professor Li's research has been focused on the development of novel gene therapies for inherited retinal diseases. His work has led to the development of Neurophth's lead product candidate, NR082, which is currently in clinical trials for the treatment of Leber's hereditary optic neuropathy (LHON), a rare genetic disorder that causes vision loss.
Neurophth's business model is based on the development and commercialization of its gene therapy products. The company plans to partner with pharmaceutical companies to bring its products to market. Neurophth's target market is the global ophthalmic market, which is estimated to be worth over $50 billion.
The company has raised over $100 million in funding from a variety of investors, including venture capital firms and strategic partners. Neurophth is headquartered in Wuhan, China, and has offices in the United States and Europe.
Keywords: gene therapy, ophthalmology, retinal diseases, Leber's hereditary optic neuropathy, clinical trials, AAV, CMC, NR082, vision loss, genetic disorders
Company overview
Neurophth company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- Wuhan, China
- Employees
- 38
- Open positions
- None listed
- Dealroom signal
- 69.7
Valuation & funding
Neurophth funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Aug 2023 | $96M | $481M | Zhejiang Paradise Silicon Valley Asset Management Group · SDIC China Merchants · Yangtze River Fund · CMB International Capital | ↗ |
| SERIES COther financing | Nov 2021 | $60M | $240M | Sunshine Insurance Group Co · HongShan · China Merchant Bank International Capital · CMG-SDIC Capital | ↗ |
| SERIES BOther financing | Feb 2021 | $55M | $220M | Harvest Capital · InnoVision Capital · Grand Mount Capital · NLVC | — |
| SERIES AOther financing | Apr 2020 | $18M | $72M | Fosun Group · HongShan | ↗ |
| SEEDOther financing | Aug 2018 | $2.1M | $8.3M | Miracle Light Fund · Mint Angel Fund · NLVC | ↗ |
| SPINOUTOther financing | Jul 2016 | Huazhong University of Science and Technology | — |
Growth signals
Neurophth website traffic
Latest recorded traffic for Neurophth is 350 monthly website visits, down 68.2% over the last three months. Neurophth's team declined 2.6% over the past year.
Comparisons
Neurophth compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Neurophth's talent
Source: Dealroom Talent Intelligence.
Investors
21 investors on Neurophth's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Neurophth has talent and traffic
team presence
In the news
Latest news about Neurophth
Recent press, funding announcements, and product moves mentioning Neurophth — open to read from the original sources.
Market sentiment
What the market is saying about Neurophth
An AI-synthesized read of the highest-engagement posts about Neurophth on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neurophth’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.